Neurocrine Biosciences, Inc. cash flow to debt ratio of 188.47% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

Neurocrine Biosciences, Inc.'s free cash flow has increased 34.37% from $557.20M last year to $748.70M, signaling increasing performance

Neurocrine Biosciences, Inc.'s debt to equity ratio is 0.11, which means that the company's assets are healthy financed, signaling financial stability.

Neurocrine Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.18 last year to 0.11 today, signaling strengthened financials

Neurocrine Biosciences, Inc. has a net cash position, so leverage is healthy.

Neurocrine Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Neurocrine Biosciences, Inc.'s profit margin has increased (44.30%) in the last year from 14.49% to 20.91%, signaling increasing performance

Neurocrine Biosciences, Inc.'s short-term assets of $2.52B exceed its short-term liabilities of $743.40M

Neurocrine Biosciences, Inc.'s return on assets of 13.16% is higher than the 5.00% threshold, indicating efficient asset utilization

Neurocrine Biosciences, Inc.'s return on equity of 21.13%, is higher than 15.00%, indicating good performance

Neurocrine Biosciences, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

Neurocrine Biosciences, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings

Neurocrine Biosciences, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

Neurocrine Biosciences, Inc. has a free cash flow yield of 4.51%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Neurocrine Biosciences, Inc.'s yearly earnings has increased 40.23% since last year from $341.30M to $478.60M, signaling increasing performance

Neurocrine Biosciences, Inc.'s yearly revenue has increased 21.45% since last year from $2.36B to $2.86B, signaling increasing performance

ROIC 13.20% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Neurocrine Biosciences, Inc.'s 3-year revenue CAGR of 24.32% is positive, indicating growing revenue over the past 3 years

Neurocrine Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Neurocrine Biosciences, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity

Neurocrine Biosciences, Inc. is overvalued relative to its fair value price of 135.38 based on Discounted Cash Flow model

Neurocrine Biosciences, Inc. has an earnings yield of 4.24%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Neurocrine Biosciences, Inc. is overvalued relative to its fair value price of 49.46 based on EBITDA multiple model

Neurocrine Biosciences, Inc. has an EV/EBITDA ratio of 23.28x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

Neurocrine Biosciences, Inc. is overvalued relative to its fair value price of 85.35 based on Earnings Fair Value model

Neurocrine Biosciences, Inc. has a PEG-ratio over 1 which is considered overvalued

Neurocrine Biosciences, Inc. has a price-to-book ratio of 4.51x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Neurocrine Biosciences, Inc. has a price-to-sales ratio of 4.94x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue